Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
HELIOS Klinikum Berlin-Buch, Akademisches LK der Universität Charité, Berlin, Germany. michael.untch@helios-kliniken.de
Neoadjuvant therapy, also known as primary, induction, or preoperative therapy, is defined as the first systemic treatment a patient receives after cancer is diagnosed and indicates that subsequent therapies are intended. It was first used in the early 1970s for the treatment of inoperable locally advanced or inflammatory breast cancer. Based on a large body of clinical evidence and on the fact that primary breast cancer is today considered a systemic disease with a locoregional component, primary systemic therapy is now increasingly considered for women with operable disease for reducing mortality with lower toxicity, improving surgical options, and acquiring early information on response and biology of the disease.
Images from this publication.See all images (4) Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on